Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level,Gleason score,or TNM status |
| |
Authors: | Petra Leidinger Martin Hart Christina Backes Stefanie Rheinheimer Bastian Keck Bernd Wullich Andreas Keller Eckart Meese |
| |
Affiliation: | 1.Institute of Human Genetics,Saarland University,Homburg,Germany;2.Chair for Clinical Bioinformatics,Saarland University,Saarbrücken,Germany;3.Department of Urology,University Hospital Erlangen,Erlangen,Germany |
| |
Abstract: | Since the benefit of prostate-specific antigen (PSA) screening remains controversial, new non-invasive biomarkers for prostate carcinoma (PCa) are still required. There is evidence that microRNAs (miRNAs) in whole peripheral blood can separate patients with localized prostate cancer from healthy individuals. However, the potential of blood-based miRNAs for the differential diagnosis of PCa and benign prostatic hyperplasia (BPH) has not been tested. We compared the miRNome from blood of PCa and BPH patients and further investigated the influence of the tumor volume, tumor-node-metastasis (TNM) classification, Gleason score, pretreatment risk status, and the pretreatment PSA value on the miRNA pattern. By microarray approach, we identified seven miRNAs that were significantly deregulated in PCa patients compared to BPH patients. Using quantitative real time PCR (qRT-PCR), we confirmed downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH. Clinical parameters like PSA level, Gleason score, or TNM status seem to have only limited impact on the overall abundance of miRNAs in patients’ blood, suggesting a no influence of these factors on the expression of deregulated miRNAs. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|